Rotigotine transdermal patch
Sponsors
UCB Pharma, UCB BIOSCIENCES GmbH, Johns Hopkins University, I.R.C.C.S. Fondazione Santa Lucia
Conditions
Alzheimer DiseaseAnxiety DisordersHealthyHealthy VolunteersParkinson DiseaseParkinson's Disease
Phase 1
Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.
CompletedNCT00881894
Start: 2008-10-31End: 2008-12-31Updated: 2014-10-27
Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body
CompletedNCT01059903
Start: 2010-01-31End: 2010-03-31Updated: 2012-05-22
Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
CompletedNCT01338896
Start: 2011-04-30End: 2011-06-30Updated: 2011-08-30
Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects
CompletedNCT01761526
Start: 2002-10-31End: 2002-12-31Updated: 2014-10-20